Additional file 4 of Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities

Pathway enrichment analysis. This Excel file contains hypergeometric test p values per pathway per disease for KEGG, BioCarta, Reactome, and PID pathway collections as well as all canonical pathway gene sets collected from MSigDB version 4.0., and Fisher’s combined p values for ASD and its co-morbidities. (XLS 1444 kb

Capability of 19-L polycarbonate plastic water cooler containers for efficient solar water disinfection (SODIS): Field case studies in India, Bahrain and Spain

The small treated volume (typically ~2 L) associated with polyethylene terephthalate (PET) bottles that are most frequently used in solar water disinfection (SODIS), is a major obstacle to uptake of this water treatment technology in resource-poor environments. In order to address this problem we have conducted a series of experiments in Spain, Bahrain and India, to assess the efficacy of large volume (19 L) transparent plastic (polycarbonate) water cooler/dispenser containers (WDCs) as SODIS reactors to inactivate Escherichia coli and Enterococcus faecalis, under strong natural sunlight. Reduction values of 6 log10 units (LRV = 6.0) have been observed using WDCs in each location. Additional comparisons between 2-L PET bottles and 19-L indicate that WDCs provide bacterial inactivation similar in both systems. SODIS disinfection experiments in turbid water (100 NTU) in both reactors showed very good inactivation efficiency. LRVs of 6 were obtained for E. coli in both WDC and 2-L PET bottles, and in the case of E. faecalis LRV = 5 and 6 were observed in Spain and Bahrain, respectively. These studies demonstrate that under conditions of strong sunlight and mild temperature, 19 L water dispenser containers can be used to provide adequate volumes of SODIS treated water for households or larger community applications such as schools or clinics in the developing world

Timeline showing periods used to calculate adherence measures and baseline variables.

<p>Outcome variable is proportion of days covered (PDC) by statin for days 91-365, respectively. Three baseline variables are calculated from the first non-statin prescription to the index date. Presence of ACS (acute coronary syndrome) as a baseline variable was determined in the 30 days prior to statin initiation. Nine baseline variables including early PDC are calculated from statin prescriptions in days 1-90. Time from eligibility to initiation is required to be 180 days (in both models) in order to include those truly initiating statins, and not those merely continuing statins after switching insurance plans. </p

Study flow diagram showing exclusion criteria.

<p>The sum of members who met each individual exclusion criterion does not equal the total number excluded because one member can meet more than one exclusion criterion.</p